Janux Therapeutics Inc (JANX)
47.51
+0.03
(+0.06%)
USD |
NASDAQ |
May 16, 16:00
47.49
-0.02
(-0.04%)
After-Hours: 20:00
Janux Therapeutics Enterprise Value: 1.812B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 1.812B |
| May 15, 2024 | 1.810B |
| May 14, 2024 | 1.832B |
| May 13, 2024 | 1.940B |
| May 10, 2024 | 1.885B |
| May 09, 2024 | 2.041B |
| May 08, 2024 | 2.219B |
| May 07, 2024 | 2.537B |
| May 06, 2024 | 2.573B |
| May 03, 2024 | 2.707B |
| May 02, 2024 | 2.585B |
| May 01, 2024 | 2.365B |
| April 30, 2024 | 2.304B |
| April 29, 2024 | 2.256B |
| April 26, 2024 | 1.805B |
| April 25, 2024 | 1.790B |
| April 24, 2024 | 1.847B |
| April 23, 2024 | 1.929B |
| April 22, 2024 | 1.882B |
| April 19, 2024 | 1.872B |
| April 18, 2024 | 1.881B |
| April 17, 2024 | 1.835B |
| April 16, 2024 | 1.969B |
| April 15, 2024 | 2.037B |
| April 12, 2024 | 2.078B |
| Date | Value |
|---|---|
| April 11, 2024 | 1.940B |
| April 10, 2024 | 1.661B |
| April 09, 2024 | 1.423B |
| April 08, 2024 | 1.351B |
| April 05, 2024 | 1.169B |
| April 04, 2024 | 1.183B |
| April 03, 2024 | 1.232B |
| April 02, 2024 | 1.208B |
| April 01, 2024 | 1.302B |
| March 31, 2024 | 1.300B |
| March 28, 2024 | 1.601B |
| March 27, 2024 | 1.615B |
| March 26, 2024 | 1.662B |
| March 25, 2024 | 1.646B |
| March 22, 2024 | 1.698B |
| March 21, 2024 | 1.715B |
| March 20, 2024 | 1.677B |
| March 19, 2024 | 1.652B |
| March 18, 2024 | 1.661B |
| March 15, 2024 | 1.694B |
| March 14, 2024 | 1.607B |
| March 13, 2024 | 1.718B |
| March 12, 2024 | 1.662B |
| March 11, 2024 | 1.721B |
| March 08, 2024 | 1.713B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-79.73M
Minimum
Nov 09 2023
2.707B
Maximum
May 03 2024
425.13M
Average
257.64M
Median
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 7.639B |
| Equillium Inc | 22.01M |
| Minerva Neurosciences Inc | -16.81M |
| Arvinas Inc | 1.044B |
| Calidi Biotherapeutics Inc | 9.220M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.76M |
| Revenue (Quarterly) | 1.252M |
| Total Expenses (Quarterly) | 21.41M |
| EPS Diluted (Quarterly) | -0.30 |
| Profit Margin (Quarterly) | -1.18K% |
| Earnings Yield | -2.55% |
| Normalized Earnings Yield | -2.547 |